| FDA Advisory Committee Recommends Approval for Vytorin in Pre-Dialysis CKD ... - Forbes |
|
|
Forbes The FDA's Endocrinologic and Metabolic Drugs Advisory Committee strongly supported the combination of ezetimibe and simvastatin (Vytorin, Merck) to prevent cardiovascular events in pre-dialysis chronic kidney disease (CKD) patients. ... Advisers back Merck drug for some kidney patients Reuters FDA Advisory Committee Unanimously Recommends Approval of Merck's VYTORIN(R |